G1 Therapeutics to Present New Clinical Data Across Pipeline at European Society for Medical Oncology (ESMO) 2019 Congress
G1 Therapeutics, Inc. (GTHX)
Last g1 therapeutics, inc. earnings: 2/26 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
g1therapeutics.com/pages/investors/investors.htm
Company Research
Source: GlobeNewswire
- Company to present first clinical data on oral SERD G1T48 in breast cancer - - Overall survival data on trilaciclib in women with metastatic triple-negative breast cancer (mTNBC) accepted for late-breaking oral presentation - - Company to host investor and analyst event, webcast and conference call at 12:45 p.m. ET on September 29, 2019 - RESEARCH TRIANGLE PARK, N.C., Sept. 10, 2019 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced new clinical data on trilaciclib, lerociclib and G1T48 will be presented at the European Society for Medical Oncology (ESMO) 2019 Congress taking place September 27 – October 1, 2019, in Barcelona, Spain. G1 Therapeutics’ four presentations include the first clinical data on the company’s oral selective estrogen receptor degrader (SERD) in estrogen receptor-positive, HER2-negative (ER+, HER2-) breast cancer, as well as data showing that trilaciclib, a first-in-class therapy to improve outco
Show less
Read more
Impact Snapshot
Event Time:
GTHX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GTHX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GTHX alerts
High impacting G1 Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
GTHX
News
- G1 Therapeutics, Inc. (NASDAQ: GTHX) had its price target lowered by analysts at Needham & Company LLC from $12.00 to $6.00. They now have a "buy" rating on the stock.MarketBeat
- G1 Therapeutics, Inc. (NASDAQ: GTHX) had its price target lowered by analysts at HC Wainwright from $9.00 to $3.00. They now have a "buy" rating on the stock.MarketBeat
- G1 Therapeutics discontinue COSELA in TNBC following Phase III flop [Yahoo! Finance]Yahoo! Finance
- G1 Therapeutics, Inc. (NASDAQ: GTHX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $3.00 price target on the stock, down previously from $5.00.MarketBeat
- G1 Therapeutics: Failure Of Breast Cancer Underscores Long-Term Uncertainty [Seeking Alpha]Seeking Alpha
GTHX
Earnings
- 5/1/24 - Miss
GTHX
Sec Filings
- 6/24/24 - Form 8-K
- 6/14/24 - Form 4
- 6/14/24 - Form 4
- GTHX's page on the SEC website